AUGTYRO® (Repotrectinib)

The FDA on June 13, 2024, granted accelerated approval to AUGTYRO® for adult and pediatric patients 12 years and older with solid tumors that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy. AUGTYRO® is a product of Bristol-Myers Squibb Company.